[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jumraini Tammasse\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":5},"100649262","msc-secretome-therapy-for-cognitive-recovery-after-subacute-ischemic-stroke-100649262",false,"NCT07731087","MSC Secretome Therapy for Cognitive Recovery After Subacute Ischemic Stroke","Efficacy of Mesenchymal Stem Cell Secretome Therapy on Cognitive Recovery in Patients With Subacute Ischemic Stroke: A Pilot Randomized Controlled Trial Using qEEG, BDNF, and Interleukin-1β Evaluation","Inclusion Criteria:\n\n1. Age 40 to 75 years.\n2. Diagnosis of ischemic stroke confirmed by clinical examination and computed tomography or magnetic resonance imaging.\n3. Stroke onset between 7 days and 3 months before enrollment.\n4. Hemodynamically stable.\n5. Able to undergo a basic neuropsychological assessment.\n6. Mild-to-moderate cognitive impairment based on the Indonesian version of the Montreal Cognitive Assessment.\n7. Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Hemorrhagic stroke or mixed ischemic and hemorrhagic stroke.\n2. Severe aphasia, impaired consciousness, or severe sensory deficits that make cognitive assessment invalid.\n3. History of dementia before stroke or a major neurodegenerative disorder.\n4. Active infection, active autoimmune disease, active malignancy, severe renal failure, or severe liver failure.\n5. Uncontrolled epilepsy.\n6. Concurrent participation in another clinical trial.\n7. Contraindication to any study intervention or study procedure.","ALL","40 Years","75 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","Post-stroke cognitive impairment can limit rehabilitation, independence, and quality of life after ischemic stroke. This pilot randomized controlled trial evaluates whether mesenchymal stem cell-derived secretome, given in addition to standard stroke care and rehabilitation, improves cognitive recovery in patients with subacute ischemic stroke. Participants aged 40 to 75 years with ischemic stroke occurring 7 days to 3 months previously and mild-to-moderate cognitive impairment will be randomly assigned in a 1:1 ratio to receive standard care and rehabilitation plus MSC secretome or standard care and rehabilitation without MSC secretome. The primary outcome is the change in the Indonesian version of the Montreal Cognitive Assessment score. Secondary outcomes include quantitative electroencephalography parameters, serum brain-derived neurotrophic factor, serum interleukin-1β, NIHSS, modified Rankin Scale, and adverse events.",[27,28],"Ischemic Stroke","Post-Stroke Cognitive Impairment",[30,31,32,33,34,35,36,37,38,39,40,41],"Subacute ischemic stroke","Post-stroke cognitive impairment","Mesenchymal stem cell secretome","MSC secretome","Cognitive recovery","MoCA-Ina","Quantitative electroencephalography","qEEG","Brain-derived neurotrophic factor","BDNF","Interleukin-1 beta","IL-1β","RECRUITING","2026-07-23",{"date":45,"type":46},"2026-07-28","ACTUAL",{"date":48,"type":46},"2026-07-09",{"date":50,"type":21},"2026-12",{"name":52,"class":53},"Jumraini Tammasse","OTHER",""]